Compare Phillips 66 (PSX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Viatris Inc — how do they compare? Phillips 66 trades at $211.8 (market cap $85.11B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Phillips 66 is far larger — about 4.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| PSX | VTRS | |
|---|---|---|
Market Cap | $85.11B | $20.50B |
Sector | Energy | Health |
52-Week High | $212.27 | $17.59 |
52-Week Low | $118.37 | $8.74 |
Enterprise Value | $107.08B | $32.71B |
Dividend Yield | 2.39% | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
